Celgene Corp. (NASDAQ:CELG) currently seems to be the best drug maker in the biotech industry, with its strong product portfolio and robust product pipeline. Brian Abrahams, analyst at Jefferies, writes about his confidence in the company’s ability to drive growth in future, in his latest research report.
Jefferies hosted Dr. Tom Daniel, President of Celgene’s Research & Early Development who spoke about the company’s excitement over how its early stage programs were expected to play out both in the short- and long-term across a variety of therapeutic areas.
